0000000000-17-001164.txt : 20170209
0000000000-17-001164.hdr.sgml : 20170209
20170111161223
ACCESSION NUMBER: 0000000000-17-001164
CONFORMED SUBMISSION TYPE: UPLOAD
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20170111
FILED FOR:
COMPANY DATA:
COMPANY CONFORMED NAME: Allergan plc
CENTRAL INDEX KEY: 0001578845
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: UPLOAD
BUSINESS ADDRESS:
STREET 1: CLONSHAUGH BUSINESS AND TECHNOLOGY PARK
CITY: COOLOCK, DUBLIN
STATE: L2
ZIP: D17 E400
BUSINESS PHONE: (216) 523-5000
MAIL ADDRESS:
STREET 1: CLONSHAUGH BUSINESS AND TECHNOLOGY PARK
CITY: COOLOCK, DUBLIN
STATE: L2
ZIP: D17 E400
FORMER COMPANY:
FORMER CONFORMED NAME: Actavis plc
DATE OF NAME CHANGE: 20130930
FORMER COMPANY:
FORMER CONFORMED NAME: Actavis Ltd
DATE OF NAME CHANGE: 20130607
PUBLIC REFERENCE ACCESSION NUMBER: 0001144204-16-117011
LETTER
1
filename1.pdf
begin 644 filename1.pdf
M)5!$1BTQ+C4-)>+CS],-"C4T(# @;V)J#3P\+TQI;F5A')E9@T*, T*)25%3T8-"B @(" @
M(" @#0HV-R P(&]B:@T\/"]#(#8F!@8&%@8+)G *_< 94P,@
MDN5H0!9C@6(&1C4&?B SP8!%JP"J.% 30C/S(BM/+( :=1@@P #:7@4-#0IE
M;F1S=')E86T-96YD;V)J#34U(# @;V)J#3P\+TQA;F2]4>7!E
M+T=R;W5P/CXO365D:6%";WA;," P(#8Q,B W.3)=+U!A7!E+T]B:E-T
M;3X^.(1C;=F9\G"[6S[A=-;^SM\[^J=J="X3.$%
MI>3:FZU;3:MR:X&2&VO6KBI!+=O*24>+B!W'N[^Q$.D,6?O<48,:_&[7W=
MD)]=NES2R>0A?&%\1$N692BYSD-UZ&'2HUW2)*]A!,U#/97&B6O&0$K566+L
M+"_0,T<9MRACU#ZGE$^_TB=OB+//8?B^>!^N'D/7
M9Z:UL7ZCS?E6K>K8 +)TU;1JW6$_=TWK+S:FZ9O_6O[PJ!#]CMR8SH-Q1K#]
M;;8ND/_"':WC;"&TY/)OX#D>@BDUF\#*8^ U/K_0'Z=U=OU
MD$K]3BKE@4K^:52.4WB\C[ZG3/;KQ%>G[]A]M0\]QT:*C^P%5@42FG3]?Q!E
M'GD,=LP(V49* W-9LKQ%6:KXQU 3)Z@QW:'&WX.:3*C]%6 X,-4'@T*96YD
M)R56%EOVS@0?@^0_S"/4A'3(BE2TJ(H
MD'/;+K+M;HWM0] 'Q:>PMI1:3X>EMEBW1:
MP=NWX^NJ2J>K^0R>QI/BY=MX\O-E/OZ<+K,\K;(B?_<.;NYNX69R>3%^X, %
M3!:7%QP"_.6@@X0E&K2.61+#9'-Y$<"27GZ_O'CRP/\&DX^7%_?(#/>/MS"V
M*+XIJJK8N'2W"B/! A&"1'U!:!3VU7Q'Y2RH?V2$P!+0B)D'"K;SRXNO;R"_
MO%!)6(O#3[EBB2&;HJSQATVZG$=P5\!?#608?R:PC[[B"P ](J9EHW@![3
M; U?_%'H5<4+A"K4'81=9AYJXNHQGSBMBX /() :+4930\54?(X0X1 B!5.-
MC(_^B =>ZH=>OJ/7K3_2WD]?!!YP?@4BX)'%K# 43"8]84Y T@&()TR>(R-T
MQ";03(A&R#\9V0+W%NA)PO0QR\@6O4"2QWNT&PR]C5PH%N@^>=\Q.!+$#@>+[BC-N6A=YN:('0K%;^EC0*_!'B7>#T=R5
M63XO2Z!8YO3AC**LO"G2KO)B71A_+NF;NNP_^R-I)&W_M1@CT(^1[.%PVI(X
M;)&:1;QK3(&0IC;-G&,"]YG9WE5W#'([@/@\"F'_N5
M/&)U QCJY2V (*+F5TOYX'-YJ+QUFL^L_4B97.XRNR$,38(&0HCE*\_SI.SM
M".)X1^!!C!(AC"(6)8W O^=8G;]9&Z4^80#K! U/:.O2TUAZ.24LO-"KM?X$
MN4O9M9W:.S1J6B-U.)Q_0YB[M \^EEJ!45;>AEIK;.U7G&9.C]U6ROC!1O^4R\,39W6"UC^>J@(AKS0I7VPT2*1.*+%.8MAI9*8F2A?[Y8[
M:Q;K
M/KN]#R4QBY,^,;>F/@:=]VEMR230WB3JTTH=Z^,=<."0(.0I*\"QM0.=0X31
M$"/QXDPZD;!GHQ:6V$-S&N#(?,CKD=5- L?5CY9KW9SFE5,"7UFE6K^FNSOA0[RIHM
M_,AHR7F]@BR'=49.K/>BRI!"L8!J111 >U"VG>+C;E-6=)PSNQQ)H:_,'GP%
MK[9#$+92G,8](^8$$U8DYH>!:.%MW1@%3+?=F%06FY=]QZCPY%SL:,6$_7*
MIKV26+1A?U@K""_288NDIT6&V\S2VAKQ1"/[>IF]SC"]CJF_DH7&--)(#QOC
MXGQ&D:!%DE,DT,5I99,KL3/CZM&3BR$!VO'1 S35>=2LI"8B,V-95I&B$C9I
MGOI--A@ )J[TE%> QYE1';I?^5YATVVU;^GP4[[@,FV,>5[/@4X?A?$J0:-C
M!D&9-G]UJE$,ZD]'7)T"-K5+4+[O3/YVR9HLM#@(CY"XC78@XB$1APQ,IC@7
M;4<=R27YL\=E.*QQX/J(X5T792[K16;5E3Z/2:L$JQ4JDLJR9(>*EQC
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MIQ8,W